Biodesix has raised $8.8 million in a Series D funding round, which it will use to boost sales of its VeriStrat assay and develop its technology platform. The Boulder, Colo.-based firm also struck a deal to get technology support from Bruker Daltonics for the VeriStrat test and future MALDI-TOF-based mass spectrometry assays.

Related Summaries